Earnings

UroGen Pharma Q3 EPS $(0.03) Misses $0.14 Estimate, Sales $89.001M Miss $89.918M Estimate

Nov 4, 2026 · 08:10 AM ET· updated 1h ago

UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $0.14 by 121.43 percent. This is a 95.65 percent increase over losses of $(0.69) per share from

Why It Matters

UroGen made less money than experts thought it would this quarter. When a company misses its targets, watch to see if it can catch up next time.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

URGN28.70

-5.70 (-16.57%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.